Carna Biosciences,Inc. (4572.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 5Aug 10Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−4.4x

Market Cap

JPY 7.83B

MomentumView details →

1D Return

+0.74%

YTD Return

+14.61%

RSI (14)

61.6

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−4.4x

Market Cap

JPY 7.83B

RSI (14)

61.6

MomentumView details →

1D Return

+0.74%

YTD Return

+14.61%

ProfitabilityView details →

Gross Margin

67.04%

Net Margin

−374.96%

EBITDA Margin

—

ROE (TTM)

−702.59%

ROA (TTM)

−176.65%

Asset Turnover

0.42x

GrowthView details →

Revenue YoY

−8.96%

EPS YoY

+8.74%

FCF YoY

—

Revenue CAGR 3Y

−25.25%

EPS CAGR 3Y

+6.59%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.03x

Current Ratio

6.99x

Quick Ratio

6.36x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

619.00M

Net Income (TTM)

−2.19B

Op. CF (TTM)

—

Next earningsNov 9, 2026 →

Latest newsMore news →

Carna Biosciences received a patent grant in Japan for manufacturing intermediates of its BTK inhibitors docirbrutinib and sofnobrutinib.16d ago

Similar companies

Tsubota Laboratory Incorporated4890.T OncoTherapy Science,Inc.4564.T Kidswell Bio Corporation4584.T Nano Holdings,Inc.4571.T Solasia Pharma K.K.4597.T CellSource Co.,Ltd.4880.T Find similar companies →

Latest newsMore news →

Carna Biosciences received a patent grant in Japan for manufacturing intermediates of its BTK inhibitors docirbrutinib and sofnobrutinib.16d ago